The Business Research Company’s report on the Remicade Biosimilar Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the remicade biosimilar market in recent years?
The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Autoimmune diseases are disorders in which the immune system mistakenly attacks and damages the body’s tissues and organs. Remicade biosimilars are used in treating autoimmune diseases by providing an effective therapeutic option to manage the symptoms and reduce inflammation associated with these. For instance, in July 2023, according to the data from the Public Health Scotland, a Scotland -based national organization, in 2022, newly diagnosed patients with multiple sclerosis (MS) increased to 87.2%, up from 85.7% in 2020, with 491 new cases reported, bringing the total to 6,359 in 2022. Therefore, the rise in the incidence of autoimmune diseases is driving the growth of the remicade biosimilar market.
Access Your Free Sample of the Global Remicade Biosimilar Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp
What is the projected market size of the remicade biosimilar industry, and how is it expected to grow?
The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.95 billion in 2024 to $4.93 billion in 2025 at a compound annual growth rate (CAGR) of 24.9%. The growth in the historic period can be attributed to the introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, and healthcare cost pressures
The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $11.07 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp
Who are the key players driving competition in the remicade biosimilar market?
Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A
What key trends are expected to drive the regulatory information management system market during the forecast period?
Product innovation is a key trend gaining popularity in the Remicade biosimilar market. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market. For instance, in January 2023, Amgen Inc., a US-based biotechnology company, launched Amjevita, a biosimilar version of AbbVie’s Humira, in the US, designed to be as safe and effective as the original drug. Amjevita is the first biosimilar to Humira and is expected to compete with Humira for market share. It is a biological drug used to treat various autoimmune diseases, including rheumatoid arthritis and Crohn’s disease. It is one of the most expensive drugs in the world, generating billions of dollars in sales for AbbVie each year. Amjevita is expected to cost significantly less. In addition to saving money, Amjevita can also offer patients more treatment options.
Which key geographies are driving the growth of the remicade biosimilar market?
Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report
What are the key segments driving growth in the remicade biosimilar market?
The remicade biosimilar market covered in this report is segmented –
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
Subsegments:
1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes
2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952
What defines the structure and scope of the remicade biosimilar market?
Remicade biosimilar refers to a biological drug like Remicade used to treat certain autoimmune diseases in adults and children. It treats autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
